Abuasab et al. conducted a study on the implementation of venetoclax and gilteritinib to intensive chemotherapy consisting of cladribine, idarubicin, and cytarabine in patients with newly diagnosed FLT3 mutated AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.